This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Bont, E. S. J. M. Articles by Bos, N. A. Search for Related Content PubMed PubMed Citation Articles by de Bont, E. S. J. M. Articles by Bos, N. A.

Mobilized Human CD34+ Hematopoietic Stem Cells Enhance Tumor Growth in a Nonobese Diabetic/Severe Combined Immunodeficient Mouse Model of Human Non-Hodgkin’s Lymphoma¹

Division of Pediatric Oncology, Department of Pediatrics [E. S. J. M. d. B., F. S., T. M., W. A. K.] and Division of Hematology, Department of Internal Medicine [E.V.], University Hospital Groningen, 9700RB Groningen, the Netherlands, and Department of Cell Biology, Section Histology and Immunology, University of Groningen, 9713 AV Groningen, the Netherlands [J. E. J. G., N. A. B.]

Autologous peripheral blood stem cell mobilization is increasingly applied in the treatment of hematological malignancies. Despite the frequent clinical use in a setting of residual disease, it is not known whether mobilization of hematopoietic stem cells might facilitate tumor outgrowth in vivo. In the bone marrow, a bipotential precursor for hematopoietic and endothelial cells called hemangioblast exists. This hemangioblast, characterized by the expression of CD34 and vascular endothelial growth factor receptor (VEGFR)-2, is released from the bone marrow by mobilization and might be able to result in not only the generation of peripheral blood cells but vasculogenesis due to differentiation of the hemangioblast along the endothelial lineage [in addition to VEGFR-2 expression, angiopoietin-2 (ANG-2) expression can also be found in this stage]. New vessel formation in the tumor is critical for tumor growth. A xenotransplant model was established with 10 x 10⁶ Daudi cells (non-Hodgkin’s lymphoma) s.c. injected in the neck region of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, who were sublethally irradiated with 2 Gy. At day 10 after tumor inoculation, half of the mice were given 0.5 x 10⁶ human CD34+ cells i.v., whereas the other half were given PBS i.v. The human CD34+ cells were obtained from leukapheresis samples of myeloma patients undergoing autologous peripheral blood stem cell mobilization. We compared tumor growth and human-specific VEGFR-2 and ANG-2 expression in the two groups. Tumor growth is enhanced 2-fold when mobilized hematopoietic human CD34+ cells are given compared with PBS controls (P = 0.004). In addition, the human-specific VEGFR-2 and ANG-2 reverse transcription-PCR was only positive in the tumors of mice i.v. injected with human CD34+ cells. This indicates that the injected human CD34+ cells home to the tumors and differentiate along the endothelial lineage. In the present study, we demonstrate that mobilized human CD34+ hematopoietic cells injected i.v. might facilitate the outgrowth of tumors in the setting of minimal residual disease. Malignant tumors are capable of incorporating human CD34+ hematopoietic cells. This study questions the safety of leukapheresis in patients with (residual) tumor and has important implications for further development of intensive chemotherapy protocols with autologous stem cell rescue.

This article has been cited by other articles:

				M. Taylor, J. Rossler, B. Geoerger, A. Laplanche, O. Hartmann, G. Vassal, and F. Farace High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies Clin. Cancer Res., July 15, 2009; 15(14): 4561 - 4571. [Abstract] [Full Text] [PDF]

				C. Igreja, M. Courinha, A. S. Cachaco, T. Pereira, J. Cabecadas, M. G. da Silva, and S. Dias Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients Haematologica, April 1, 2007; 92(4): 469 - 477. [Abstract] [Full Text] [PDF]

				R. G. Bagley, W. Weber, C. Rouleau, and B. A. Teicher Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy Cancer Res., November 1, 2005; 65(21): 9741 - 9750. [Abstract] [Full Text] [PDF]

				H. Zhang, V. Vakil, M. Braunstein, E. L. P. Smith, J. Maroney, L. Chen, K. Dai, J. R. Berenson, M. M. Hussain, U. Klueppelberg, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood, April 15, 2005; 105(8): 3286 - 3294. [Abstract] [Full Text] [PDF]

				C. Rabascio, E. Muratori, P. Mancuso, A. Calleri, V. Raia, T. Foutz, S. Cinieri, G. Veronesi, G. Pruneri, P. Lampertico, et al. Assessing Tumor Angiogenesis: Increased Circulating VE-Cadherin RNA in Patients with Cancer Indicates Viability of Circulating Endothelial Cells Cancer Res., June 15, 2004; 64(12): 4373 - 4377. [Abstract] [Full Text] [PDF]

				Y. J. Liu, S. H. Lu, B. Xu, R. C. Yang, Q. Ren, B. Liu, B. Li, M. Lu, F. Y. Yan, Z. B. Han, et al. Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages Blood, June 15, 2004; 103(12): 4449 - 4456. [Abstract] [Full Text] [PDF]

				D. W. Losordo and S. Dimmeler Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part II: Cell-Based Therapies Circulation, June 8, 2004; 109(22): 2692 - 2697. [Full Text] [PDF]

				S. Le Ricousse-Roussanne, V. Barateau, J.-o. Contreres, B. Boval, L. Kraus-Berthier, and G. Tobelem Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature Cardiovasc Res, April 1, 2004; 62(1): 176 - 184. [Abstract] [Full Text] [PDF]

				L. V. Beerepoot, N. Mehra, J. S. P. Vermaat, B. A. Zonnenberg, M. F. G. B. Gebbink, and E. E. Voest Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients Ann. Onc., January 1, 2004; 15(1): 139 - 145. [Abstract] [Full Text] [PDF]

				R. G. Bagley, J. Walter-Yohrling, X. Cao, W. Weber, B. Simons, B. P. Cook, S. D. Chartrand, C. Wang, S. L. Madden, and B. A. Teicher Endothelial Precursor Cells As a Model of Tumor Endothelium: Characterization and Comparison with Mature Endothelial Cells Cancer Res., September 15, 2003; 63(18): 5866 - 5873. [Abstract] [Full Text] [PDF]

				F. Bertolini, S. Paul, P. Mancuso, S. Monestiroli, A. Gobbi, Y. Shaked, and R. S. Kerbel Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells Cancer Res., August 1, 2003; 63(15): 4342 - 4346. [Abstract] [Full Text] [PDF]